Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-08
2005-11-08
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S256000, C514S291000, C514S302000, C514S312000, C514S313000, C514S314000, C514S333000, C514S336000, C514S337000, C514S339000, C514S341000, C514S343000, C514S393000, C514S397000, C514S411000, C514S414000, C514S422000, C544S335000, C546S090000, C546S115000, C546S153000, C546S157000, C546S159000, C546S169000, C546S171000, C546S173000, C546S175000, C546S256000, C546S273100, C546S274100, C546S277400, C546S277700, C546S278100, C546S278400, C548S303100, C548S314700, C548S430000, C548S431000, C548S467000, C548S
Reexamination Certificate
active
06962942
ABSTRACT:
The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds having Formula I:or pharmaceutically acceptable salts thereof; whereinQ is phenyl, benzyl, pyridyl, thienyl, indolyl, quinolinyl, benzothienyl, biphenylyl, or imidazolyl; any of which can include one or more optional substituents independently selected from halo, trifluoromethyl, hydroxy, amino, nitro, cyano, C1alkoxy, C1-3alkyl, methylenedioxy, carboxamido, acetamido, or amidino;X is methylene, carbonyl, or sulfonyl; Z is methylene, ethylene, or propylene; M is methylene or ethylene; andR1R2and R3are independently hydrogen or C1-3alkyl.
REFERENCES:
patent: 4727064 (1988-02-01), Pitha
patent: 4764604 (1988-08-01), Müller
patent: 5024998 (1991-06-01), Bodor
patent: 5385885 (1995-01-01), Gasic et al.
patent: 5703208 (1997-12-01), Semple et al.
patent: 5891909 (1999-04-01), Soll et al.
patent: 6037356 (2000-03-01), Lu et al.
patent: 0 526 877 (1993-02-01), None
patent: 09165370 (1997-06-01), None
patent: WO 93/01208 (1993-01-01), None
patent: WO 94/20535 (1994-09-01), None
patent: WO 95/35311 (1995-12-01), None
patent: WO 97/01338 (1997-01-01), None
patent: WO 97/30073 (1997-08-01), None
patent: WO 97/30708 (1997-08-01), None
patent: WO 98/16523 (1998-04-01), None
patent: WO 99/07731 (1999-02-01), None
patent: WO 99/07732 (1999-02-01), None
Bromberg, M.E., et al., “Cancer and Blood Coagulation: Molecular Aspects,”Cancer J. 5:132-138, Scientific American, Ltd. (May/Jun. 1999).
Cirino, G., et al., “Factor Xa as an Interface Between Coagulation and Inflammation. Molecular Mimicry of Factor Xa Association with Effector Cell Protease Receptor-1 Induces Acute Inflammation In Vivo,”J. Clin. Invest. 99:2446-2451, The American Society for Clinical Investigation, Inc. (1997).
Edmunds, J.J., and Rapundalo, S.T., “Thrombin and Factor Xa Inhibition,”Ann. Rep. Med. Chem. 31:51-60, Academic Press, Inc. (1996).
Esmon, C.T., “Role of Coagulation Inhibitors in Inflammation,”Thromb. Haemost. 86:51-56, Schattauer GmbH, Stuttgart (Jul. 2001).
Haas, C., et al., “Proteolysis of Alzheimer's disease β-amyloid precursor protein by factor Xa,”Biochim. Biophys. Acta 1343:85-94, Elsevier Science B.V. (1997).
Ornstein, D.L., and Zacharski, L.R., “Treatment of Cancer with Anticoagulants: Rationale in the Treatment of Melanoma,”Int. J. Hematol. 73:157-161, Carden Jennings Publishing (Feb. 2001).
CAPLUS Accession No. 1997:479333, Document No. 127:121652, CAPLUS English lanugage abstract, American Chemical Society, for JP 09165370 (Document AL3), Jun. 1997.
CAPLUS Accession No. 1993:428019, Document No. 119:28019, CAPLUS English language abstract, American Chemical Society, for WO 93/01208 (Document AN2), Jan. 1993.
European Patent Office: Patent Abstracts of Japan, English language abstract, Japanese Patent Office, for JP 09165370 (Document AL3), Jun. 1997.
International Search Report for International Application No. PCT/US00/25006 mailed on Dec. 13, 2000.
Dialog File 351, WPI Accession No. 1993-009740/199302, Derwent WPI English language abstract for WO 93/01208 (Document AN2), Jan. 1993.
Adang, A.E.P., et al., “Novel Acylguanidine Containing Thrombin Inhibitors with Reduced Basicity at the P1 Moiety,”Bioorg. Med. Chem. Lett. 8:3603-3608 (Dec. 1998).
Brown, F.J., et al., “Design of Orally Active, Non-Peptidic Inhibitors of Human Leukocyte Elastase,”J. Med. Chem. 37:1259-1261 (Apr. 1994).
Coughlin, S.R., “Molecular Mechanisms of Thrombin Signaling,”Seminars in Hematology 31:270-277 (Oct. 1994).
Cuypers, H.T., et al., “Sulfhydryl Content of Bovine Eye Lens Leucine Aminopeptidase,”J. Biol. Chem. 257:7086-7091 (Jun. 1982).
Freidinger, R.M., et al., “Protected Lactam-Bridged Dipeptides for Use as Conformational Constraints in Peptides,”J. Org. Chem. 47:104-109 (Jan. 1982).
Glaeson, G., “Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System,”0Blood Coagulation and Fibrinolysis 5:411-436 (Jun. 1994).
Hara, T., et al., “DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa,”Thrombosis Haemostasis 71:314-319 (Mar. 1994).
Harker, L.A., “Strategies for Inhibiting the Effects of Thrombin,”Blood Coagulation and Fibrinolysis 5:S47-S58 (Jan. 1994).
Kawasaki, T., et al., “Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patency in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis,”Thromb. Haemost. 79:859-864 (Apr. 1998).
Krishnan, R., et al., “Highly Selective Mechanism-Based Thrombin Inhibitors: Structures of Thrombin and Trypsin Inhibited with Rigid Peptidyl Aldehydes,”Biochemistry 37:12094-12103 (Nov. 1998).
Lefkovits, J., et al., “Direct Thrombin Inhibitors in Cardiovascular Medicine,”Circulation 90:1522-1536 (Sep. 1994).
Levy, O.E., et al., “Potent and Selective Thrombin Inhibitors Incorporating the Constrained Arginine Mimic L-3-Piperidyl(N-guanidino)alanine at P1,”J. Med. Chem. 39:4527-4530 (Nov. 1996).
Lu, T., et al., “In Vitro Evaluation and Crystallographic Analysis of a New Class of Selective, Non-Amide-Based Thrombin Inhibitors,”Bioorg. Med. Chem. Lett. 8:1595-1600 (Jul. 1998).
Lu, T., et al., “Structure-Activity and Crystallographic Analysis of a New Class of Non-amide-Based Thrombin Inhibitor,”Bioorg. Med. Chem. Lett. 10:79-82 (Jan. 2000).
Markwardt, F., “Inventory of Coagulation Inhibitors from Animals Feeding on Blood,”Thrombosis and Haemostasis 72:477-480 (Sep. 1994).
Meilott, M.J., et al., “Acceleration of Recombinant Tissue-Type Plasminogen Activator-Induced Reperfusion and Prevention of Reocclusion by Recombinant Antistasin, a Selective Factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis,”Circulation Res. 70:1152-1160 (Jun. 1992).
Morishima, Y., et al., “Antithrombotic and Hemorrhagic Effects of DX-9065a, a Direct and Selective Factor Xa Inhibitor: Comparison with a Direct Thrombin Inhibitor and Antithrombin III-Dependent Anticoagulants,”Thromb. Haemost. 78:1366-1371 (Nov. 1997).
Nagahara, T., et al., “Dibasic (Amidinoaryl)propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors,”J. Med. Chem. 37:1200-1207 (Apr. 1994).
Nutt, R.F., et al., “Discovery and Development of Potent, Selective and Orally Bioavailable Thrombin Inhibitors,”Peptides 1996 Proceedings of the Twenty-Fourth Eurpean Peptide Symposium, eds. Ramage, R. and Epton R., Sep. 8-13, 1996, Mayflower Scientific Ltd., 71-74.
Prasa, D., et al., “Inhibition of Thrombin Generation in Plasma by Inhibitors of Factor Xa,”Thromb. Haemost. 78:1215-1220 (Oct. 1997).
Ragosta, M., et al., “Specific Factor Xa Inhibition Reduces Restenosis After Balloon Angioplasty of Atheroslerotic Femoral Arteries in Rabbits,”Circulation 89:1262-1271 (Mar. 1994).
Rewinkel, J.B.M., et al., “Strategies and Progress Towards the Ideal Orally Active Thrombin Inhibitor,”Curr. Pharm. Des. 5:1043-1075 (Dec. 1999).
Scholtz, J.M., et al., “A Convenient Differential Protection Strategy for Functional Group Manipulation of Aspartic and Glutamic Acids,”Synthesis477-570 (Jul. 1989).
Semple, J.E., et al., “Design and Construction of Novel Thrombin Inhibitors Featuring P3-P4 Quaternary Lactam Dipeptide Surrogates,”Bioorg. Med. Chem. Lett. 8:2501-2506 (Sep. 1998).
Semple, J.E., et al., “Design, Synthesis, and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-Argininal Derivatives Incorporating P3-P4 Lactam Sulfonamide Moieties,”J. Med
Hall Jonathan
Haslow Kristin D.
Miller Scott C.
Sánchez Juan José Marugán
3-Dimensional Pharmaceuticals Inc.
Coleman Brenda
Woodcock & Washburn LLP
LandOfFree
Azacycloalkanone serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azacycloalkanone serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azacycloalkanone serine protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3517349